SHCBP1在恶性肿瘤中的作用机制及临床研究进展

doi:10.3760/cma.j.cn371439-20250331-00098

摘要/Abstract

摘要：

SHCBP1是一种可特异性结合SH2结构域的Src同源胶原蛋白，可作为关键调控蛋白，在多种恶性肿瘤中呈异常高表达，通过影响细胞周期、增殖和侵袭等过程，参与肿瘤的发生与发展。此外，SHCBP1高表达与多种恶性肿瘤化疗耐药及不良预后密切相关，靶向抑制可增强化疗敏感性，为多种实体瘤提供新的治疗策略，是重要的预后评估生物标志物和潜在治疗靶点。

关键词: 肿瘤, 含Src同源结构域2转化蛋白质1, 细胞增殖, 细胞运动, 肿瘤微环境, 预后

Abstract:

SHCBP1 is a type of Src homologous collagen that can specifically bind to the SH2 structural domain. It can act as a key regulatory protein， and exhibits abnormally high expression in a variety of malignant tumors. Through affecting the processes such as cell cycle， proliferation， and invasion， it participates in tumor genesis and development. In addition， high expression of SHCBP1 is closely related to chemotherapy resistance and poor prognosis of many malignant tumors， and its targeted inhibition can enhance the sensitivity of chemotherapy and provide new therapeutic strategies for a variety of solid tumors， making it an important biomarker for prognostic assessment and a potential therapeutic target.

Key words: Neoplasms, Src homology 2 domain-containing， transforming protein 1, Cell proliferation, Cell movement, Tumor microenvironment, Prognosis

刘美, 胡玉崇, 李凤桐, 朝乐门, 柳檬, 亢琳琳. SHCBP1在恶性肿瘤中的作用机制及临床研究进展[J]. 国际肿瘤学杂志, 2025, 52(9): 583-586.

Liu Mei, Hu Yuchong, Li Fengtong, Chao Lemen, Liu Meng, Kang Linlin. Mechanism of action of SHCBP1 in malignant tumors and progress in clinical research[J]. Journal of International Oncology, 2025, 52(9): 583-586.

参考文献 35

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Yao J, Huang X, Sun Q, et al. Hypoxic stimulation of DCLK1 transcription and alternative-promoter switching fuels tumor malignancy in clear cell renal cell carcinoma[J]. Cell Death Dis, 2025, 16(1): 594. DOI: 10.1038/s41419-025-07916-2.
[3]	Lin Y, Cai H. Biological functions and therapeutic potential of SHCBP1 in human cancer[J]. Biomed Pharmacother, 2023, 160: 114362. DOI: 10.1016/j.biopha.2023.114362.
[4]	Wang N, Zhu L, Wang L, et al. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers[J]. Comput Struct Biotechnol J, 2022, 20: 3106-3119. DOI: 10.1016/j.csbj.2022.06.039.
[5]	Zhou M, Duan L, Chen J, et al. The dynamic role of nucleoprotein SHCBP1 in the cancer cell cycle and its potential as a synergistic target for DNA-damaging agents in cancer therapy[J]. Cell Commun Signal, 2024, 22(1): 131. DOI: 10.1186/s12964-024-01513-0.
[6]	Yu X, Sun Z, Nie S, et al. Effects of resveratrol on mouse B16 melanoma cell proliferation through the SHCBP1-ERK1/2 signaling pathway[J]. Molecules, 2023, 28(22): 7614. DOI: 10.3390/molecules28227614.
[7]	Deng B, Li A, Zhu Y, et al. SHCBP1 contributes to the proliferation and self‑renewal of cervical cancer cells and activation of the NF‑κB signaling pathway through EIF5A[J]. Oncol Lett, 2023, 25(6): 246. DOI: 10.3892/ol.2023.13832.
[8]	Lu H, Yin M, Wang L, et al. FGF13 interaction with SHCBP1 activates AKT-GSK3α/β signaling and promotes the proliferation of A549 cells[J]. Cancer Biol Ther, 2020, 21(11): 1014-1024. DOI: 10.1080/15384047.2020.1824512. pmid: 33064958
[9]	Tang C, Peng S, Chen Y, et al. SHCBP1 is a novel regulator of PLK1 phosphorylation and promotes prostate cancer bone metastasis[J]. MedComm, 2025, 6(2): e70082. DOI: 10.1002/mco2.70082.
[10]	Dai Y, Hu C, Zhou H, et al. Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway[J]. FEBS J, 2023, 290(24): 5720-5743. DOI: 10.1111/febs.16933. pmid: 37581853
[11]	Sun Y, Pan H, He Y, et al. Functional roles of the SHCBP1 and KIF23 interaction in modulating the cell-cycle and cisplatin resistance of head and neck squamous cell carcinoma[J]. Head Neck, 2022, 44(3): 591-605. DOI: 10.1002/hed.26961.
[12]	Yang C, Hu JF, Zhan Q, et al. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer[J]. Genomics, 2021, 113(2): 827-842. DOI: 10.1016/j.ygeno.2021.01.010. pmid: 33515675
[13]	Gao W, Qi CQ, Feng MG, et al. SOX2-induced upregulation of lncRNA LINC01561 promotes non-small-cell lung carcinoma progression by sponging miR-760 to modulate SHCBP1 expression[J]. J Cell Physiol, 2020, 235(10): 6684-6696. DOI: 10.1002/jcp.29564. pmid: 32003010
[14]	Qi G, Ma H, Teng K, et al. SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway[J]. Apoptosis, 2025, 30(1): 83-98. DOI: 10.1007/s10495-024-02027-3.
[15]	Yu X, Feng G, Nian R, et al. SHCBP1 promotes the proliferation of breast cancer cells by inhibiting CXCL2[J]. J Cancer, 2023, 14(18): 3444-3456. DOI: 10.7150/jca.88072. pmid: 38021148
[16]	Ren C, Zhou Z, Wang X, et al. SHCBP1 promotes the progression of esophageal squamous cell carcinoma via the TGFβ pathway[J]. Appl Immunohistochem Mol Morphol, 2021, 29(2): 136-143. DOI: 10.1097/pai.0000000000000858.
[17]	Mo M, Tong S, Yin H, et al. SHCBP1 regulates STAT3/c-Myc signaling activation to promote tumor progression in penile cancer[J]. Am J Cancer Res, 2020, 10(10): 3138-3156. pmid: 33163262
[18]	Luo Y, Zhang S, Xie H, et al. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma[J]. Cell Mol Biol (Noisy-le-grand), 2023, 69(14): 51-61. DOI: 10.14715/cmb/2023.69.14.9. pmid: 38279482
[19]	Sauzeau V, Beignet J, Bailly C. Rac1 as a target to treat dysfunctions and cancer of the bladder[J]. Biomedicines, 2022, 10(6): 1357. DOI: 10.3390/biomedicines10061357.
[20]	Yin H, Zhang C, Wei Z, et al. EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation[J]. Cell Death Dis, 2022, 13(1): 39. DOI: 10.1038/s41419-021-04479-w.
[21]	Huang H, Cai H, Zhang L, et al. Oroxylin a inhibits carcinogen-induced skin tumorigenesis through inhibition of inflammation by regulating SHCBP1 in mice[J]. Int Immunopharmacol, 2020, 80: 106123. DOI: 10.1016/j.intimp.2019.106123.
[22]	Zhong A, Chen T, Xing Y, et al. FUCA2 is a prognostic biomarker and correlated with an immunosuppressive microenvironment in pan-cancer[J]. Front Immunol, 2021, 12: 758648. DOI: 10.3389/fimmu.2021.758648.
[23]	Huang Y, You M, Wu Q, et al. SHCBP1 is a prognostic biomarker related to the tumour immune microenvironment in pan-cancer[J]. Ann Clin Lab Sci, 2022, 52(6): 904-917. pmid: 36564070
[24]	Jiang F, Shi Y, Wang Y, et al. Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets[J]. Aging (Albany NY), 2023, 15(6): 2066-2081. DOI: 10.18632/aging.204591.
[25]	Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer[J]. Nat Rev Cancer, 2021, 21(6): 345-359. DOI: 10.1038/s41568-021-00347-z. pmid: 33837297
[26]	Chen G, Li W, Ge R, et al. NUSAP1 promotes immunity and apoptosis by the SHCBP1/JAK2/STAT3 phosphorylation pathway to induce dendritic cell generation in hepatocellular carcinoma[J]. J Immunother, 2025, 48(2): 46-57. DOI: 10.1097/cji.0000000000000531.
[27]	Mo L, Deng M, Adhav R, et al. Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapy[J]. Cell Death Dis, 2025, 16(1): 220. DOI: 10.1038/s41419-025-07570-8.
[28]	Xu N, Wu YP, Yin HB, et al. SHCBP1 promotes tumor cell proli-feration, migration, and invasion, and is associated with poor prostate cancer prognosis[J]. J Cancer Res Clin Oncol, 2020, 146(8): 1953-1969. DOI: 10.1007/s00432-020-03247-1.
[29]	Lin K, Hu K, Chen Q, et al. The function and immune role of cuproptosis associated hub gene in Barrett's esophagus and esophageal adenocarcinoma[J]. Biosci Trends, 2023, 17(5): 381-392. DOI: 10.5582/bst.2023.01164. pmid: 37866883
[30]	Zhou Q, Liu X, Lv M, et al. Genes that predict poor prognosis in breast cancer via bioinformatical analysis[J]. Biomed Res Int, 2021, 2021: 6649660. DOI: 10.1155/2021/6649660.
[31]	Liu N, Zhang GD, Bai P, et al. Eight hub genes as potential biomarkers for breast cancer diagnosis and prognosis: a TCGA-based study[J]. World J Clin Oncol, 2022, 13(8): 675-688. DOI: 10.5306/wjco.v13.i8.675. pmid: 36160462
[32]	Senter NC, McCulley A, Kuznetsov VA, et al. Identification of recurrent chromosome breaks underlying structural rearrangements in mammary cancer cell lines[J]. Genes (Basel), 2022, 13(7): 1228. DOI: 10.3390/genes13071228.
[33]	Shi W, Zhang G, Ma Z, et al. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer[J]. Nat Commun, 2021, 12(1): 2812. DOI: 10.1038/s41467-021-23053-8.
[34]	Moghimi A, Bani Hosseinian N, Mahdipour M, et al. Deciphering the molecular complexity of hepatocellular carcinoma: unveiling novel biomarkers and therapeutic targets through advanced bioinformatics analysis[J]. Cancer Rep (Hoboken), 2024, 7(8): e2152. DOI: 10.1002/cnr2.2152.
[35]	Cao J, Yu C. Identification of immune infiltration and prognostic biomarkers in small cell lung cancer based on bioinformatic methods from 3 studies[J]. Comb Chem High Throughput Screen, 2023, 26(3): 507-516. DOI: 10.2174/1386207325666220408092925.